{"id":"NCT00752973","sponsor":"Sun Pharmaceutical Industries, Inc.","briefTitle":"Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice","officialTitle":"Phase II, Multi-Center, Open-Label, Safety and Tolerance Study of a Novel Malathion Formulation in Infants and Toddlers With Pediculosis Capitis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-09","primaryCompletion":"2011-12","completion":"2012-01","firstPosted":"2008-09-16","resultsPosted":"2014-04-03","lastUpdate":"2014-08-07"},"enrollment":12,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pediculosis"],"interventions":[{"type":"DRUG","name":"MALG (malathion) Treatment","otherNames":["Novel malathion formulation"]}],"arms":[{"label":"Treatment arm","type":"EXPERIMENTAL"}],"summary":"In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population.\n\nThe current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.","primaryOutcome":{"measure":"Participants With a Change in Cholinesterase Level at 1 Hour (Day 0).","timeFrame":"Change from Baseline to 1 hour","effectByArm":[{"arm":"MALG (Malathion Gel, 0.5% )Treatment Arm","deltaMin":-1.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":["17845167"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Cough","Diarrhoea","Head injury","Wheezing"]}}